ViRexx is Alan's company. We see OvaRex as sitting in a middle ground between MAbs and active immunotherapies. We are also not fans of the company's licensing deals, but think the company is cheap enough that a win in the OvaRex trials will make investors some money.
Market Data 
Markets 
AI
